People · Operator
Named in public records as an officer, director or promoter · active 2010–2023 · Biotechnology, Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Pluri Inc. | — | Biotechnology | Series A | $13.4M | $13.8M | 2010 |
| Scinai Immunotherapeutics Ltd. | — | Pharmaceuticals | Seed | $3.0M | $10.5M | 2023 |
Mark Germain at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Mark Germain on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Doron Birger | 1 | 3 |
| Chen Franco-Yehuda | 1 | 3 |
| Yael Margolin | 1 | 2 |
| Uri Ben Or | 1 | 2 |
| Nachum Rosman | 1 | 1 |
| Yaky Yanay | 1 | 1 |
| Shai Pines | 1 | 1 |
| Isaac Braun | 1 | 1 |
| Alejandro Weinstein | 1 | 1 |
| Liat Zalts | 1 | 1 |
| Rami Levi | 1 | 1 |
| Doron Shorrer | 1 | 1 |
| Maital Shemesh-Rasmussen | 1 | 1 |
| Varda Shalev | 1 | 1 |
| Elad Mark | 1 | 1 |
| Morris Laster | 1 | 1 |
| Amir Reichman | 1 | 1 |
| Tamar Ben-Yedidia | 1 | 1 |
| Adi Raviv | 1 | 1 |
| Samuel Moed | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.